Literature DB >> 22669455

Use of panitumumab-IRDye800 to image microscopic head and neck cancer in an orthotopic surgical model.

C Hope Heath1, Nicholas L Deep, Larissa Sweeny, Kurt R Zinn, Eben L Rosenthal.   

Abstract

BACKGROUND: Fluorescence imaging hardware (SPY) has recently been developed for intraoperative assessment of blood flow via detection of probes emitting in the near-infrared (NIR) spectrum. This study sought to determine if this imaging system was capable of detecting micrometastatic head and neck squamous cell carcinoma (HNSCC) in preclinical models.
METHODS: A NIR fluorescent probe (IRDye800CW) was covalently linked to a monoclonal antibody targeting epidermal growth factor receptor (EGFR; panitumumab) or nonspecific IgG. HNSCC flank (SCC-1) and orthotopic (FADU and OSC19) xenografts were imaged 48-96 h after systemic injection of labeled panitumumab or IgG. The primary tumor and regional lymph nodes were dissected using fluorescence guidance with the SPY system and grossly assessed with a charge-coupled NIR system (Pearl). Histologic slides were also imaged with a NIR charged-coupled device (Odyssey) and fluorescence intensity was correlated with pathologic confirmation of disease.
RESULTS: Orthotopic tongue tumors were clearly delineated from normal tissue with tumor-to-background ratios of 2.9 (Pearl) and 2.3 (SPY). Disease detection was significantly improved with panitumumab-IRDye compared to IgG-IRDye800 (P < 0.05). Tissue biopsy samples (average size 3.7 mm) positive for fluorescence were confirmed for pathologic disease by histology and immunohistochemistry (n = 25 of 25). Biopsy samples of nonfluorescent tissue were proven to be negative for malignancy (n = 28 of 28). The SPY was able to detect regional lymph node metastasis (<1.0 mm) and microscopic areas of disease. Standard histological assessment in both frozen and paraffin-embedded histologic specimens was augmented using the Odyssey.
CONCLUSIONS: Panitumumab-IRDye800 may have clinical utility in detection and removal of microscopic HNSCC using existing intraoperative optical imaging hardware and may augment analysis of frozen and permanent pathology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22669455      PMCID: PMC3595117          DOI: 10.1245/s10434-012-2435-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  20 in total

1.  A quantitative analysis of rate-limiting steps in the metastatic cascade using human-specific real-time polymerase chain reaction.

Authors:  Andries Zijlstra; Rebecca Mellor; Giano Panzarella; Ronald T Aimes; John D Hooper; Natalia D Marchenko; James P Quigley
Journal:  Cancer Res       Date:  2002-12-01       Impact factor: 12.701

Review 2.  The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy.

Authors:  Rebecca G Pomerantz; Jennifer Rubin Grandis
Journal:  Semin Oncol       Date:  2004-12       Impact factor: 4.929

3.  Clinical utility of intraoperative frozen section diagnosis in head and neck surgery: a quality assurance perspective.

Authors:  R F Gandour-Edwards; P J Donald; J T Lie
Journal:  Head Neck       Date:  1993 Sep-Oct       Impact factor: 3.147

4.  Reliability of frozen section diagnosis in head and neck neoplasms.

Authors:  K A Remsen; F E Lucente; H F Biller
Journal:  Laryngoscope       Date:  1984-04       Impact factor: 3.325

Review 5.  Epidermal growth factor receptor expression and measurement in solid tumors.

Authors:  David C Spaulding; Betsy O Spaulding
Journal:  Semin Oncol       Date:  2002-10       Impact factor: 4.929

6.  In vivo detection of head and neck cancer orthotopic xenografts by immunofluorescence.

Authors:  Eben L Rosenthal; Brian D Kulbersh; Ryan D Duncan; Wenyue Zhang; J Scott Magnuson; William R Carroll; Kurt Zinn
Journal:  Laryngoscope       Date:  2006-09       Impact factor: 3.325

7.  Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer.

Authors:  Kristen E Adams; Shi Ke; Sunkuk Kwon; Feng Liang; Zhen Fan; Yang Lu; Karen Hirschi; Michel E Mawad; Michael A Barry; Eva M Sevick-Muraca
Journal:  J Biomed Opt       Date:  2007 Mar-Apr       Impact factor: 3.170

8.  Assessment of indocyanine green-labeled cetuximab to detect xenografted head and neck cancer cell lines.

Authors:  Kirk P Withrow; John P Gleysteen; Ahmad Safavy; Joni Skipper; Renee A Desmond; Kurt Zinn; Eben L Rosenthal
Journal:  Otolaryngol Head Neck Surg       Date:  2007-11       Impact factor: 3.497

9.  Fluorescently labeled cetuximab to evaluate head and neck cancer response to treatment.

Authors:  John P Gleysteen; Ryan D Duncan; J Scott Magnuson; Joni B Skipper; Kurt Zinn; Eben L Rosenthal
Journal:  Cancer Biol Ther       Date:  2007-05-03       Impact factor: 4.742

10.  Sensitivity and specificity of fluorescent immunoguided neoplasm detection in head and neck cancer xenografts.

Authors:  Brian D Kulbersh; Ryan D Duncan; J Scott Magnuson; Joni B Skipper; Kurt Zinn; Eben L Rosenthal
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2007-05
View more
  56 in total

1.  Review of fluorescence guided surgery visualization and overlay techniques.

Authors:  Jonathan T Elliott; Alisha V Dsouza; Scott C Davis; Jonathan D Olson; Keith D Paulsen; David W Roberts; Brian W Pogue
Journal:  Biomed Opt Express       Date:  2015-09-03       Impact factor: 3.732

2.  Delta-Opioid Receptor (δOR) Targeted Near-Infrared Fluorescent Agent for Imaging of Lung Cancer: Synthesis and Evaluation In Vitro and In Vivo.

Authors:  Allison S Cohen; Renata Patek; Steven A Enkemann; Joseph O Johnson; Tingan Chen; Eric Toloza; Josef Vagner; David L Morse
Journal:  Bioconjug Chem       Date:  2015-10-30       Impact factor: 4.774

3.  Preclinical studies on tumor-specific fluorescent targeting agents: the need for a gold standard of tumor localization.

Authors:  Stijn Keereweer; Pieter B A A Van Driel; Clemens W G M Lowik
Journal:  Mol Imaging Biol       Date:  2014-02       Impact factor: 3.488

4.  Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer.

Authors:  Eben L Rosenthal; Jason M Warram; Esther de Boer; Thomas K Chung; Melissa L Korb; Margie Brandwein-Gensler; Theresa V Strong; Cecelia E Schmalbach; Anthony B Morlandt; Garima Agarwal; Yolanda E Hartman; William R Carroll; Joshua S Richman; Lisa K Clemons; Lisle M Nabell; Kurt R Zinn
Journal:  Clin Cancer Res       Date:  2015-04-22       Impact factor: 12.531

5.  Comparison of Panitumumab-IRDye800CW and 5-Aminolevulinic Acid to Provide Optical Contrast in a Model of Glioblastoma Multiforme.

Authors:  Tiara S Napier; Neha Udayakumar; Aditi H Jani; Yolanda E Hartman; Hailey A Houson; Lindsay Moore; Hope M Amm; Nynke S van den Berg; Anna G Sorace; Jason M Warram
Journal:  Mol Cancer Ther       Date:  2020-06-30       Impact factor: 6.261

Review 6.  Fluorescent imaging of cancerous tissues for targeted surgery.

Authors:  Lihong Bu; Baozhong Shen; Zhen Cheng
Journal:  Adv Drug Deliv Rev       Date:  2014-07-24       Impact factor: 15.470

7.  Antiangiogenic antibody improves melanoma detection by fluorescently labeled therapeutic antibodies.

Authors:  Larissa Sweeny; Andrew Prince; Neel Patel; Lindsay S Moore; Eben L Rosenthal; Brian B Hughley; Jason M Warram
Journal:  Laryngoscope       Date:  2016-08-31       Impact factor: 3.325

8.  Tumor margin detection using quantitative NIRF molecular imaging targeting EpCAM validated by far red gene reporter iRFP.

Authors:  Banghe Zhu; Grace Wu; Holly Robinson; Nathaniel Wilganowski; Mary A Hall; Sukhen C Ghosh; Kenneth L Pinkston; Ali Azhdarinia; Barrett R Harvey; Eva M Sevick-Muraca
Journal:  Mol Imaging Biol       Date:  2013-10       Impact factor: 3.488

9.  Fluorescently labeled therapeutic antibodies for detection of microscopic melanoma.

Authors:  Kristine E Day; Lauren N Beck; Nicholas L Deep; Joy Kovar; Kurt R Zinn; Eben L Rosenthal
Journal:  Laryngoscope       Date:  2013-04-24       Impact factor: 3.325

10.  Use of panitumumab-IRDye800 to image cutaneous head and neck cancer in mice.

Authors:  C Hope Heath; Nicholas L Deep; Lauren N Beck; Kristine E Day; Larissa Sweeny; Kurt R Zinn; Conway C Huang; Eben L Rosenthal
Journal:  Otolaryngol Head Neck Surg       Date:  2013-03-22       Impact factor: 3.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.